Perceive Biotherapeutics

Executive Summary

Perceive Biotherapeutics is a private biotechnology company established in 2021 and headquartered in Cambridge, MA, dedicated to developing novel therapeutics for retinal degenerative diseases. Leveraging deep genetic insights and over two decades of academic research, the company targets protective biological pathways to prevent irreversible blindness, with an initial focus on dry age-related macular degeneration (AMD) and neuroprotection. Perceive employs multiple therapeutic modalities, including biologics, to differentiate its pipeline and address high unmet medical needs in ophthalmology. The company's approach is grounded in translating fundamental protective biology into clinical candidates, positioning it as a potential leader in the retinal degeneration space. While Perceive is in early stages with no disclosed pipeline details on public databases, its scientific foundation and focus on a large and growing patient population suggest significant potential. The company has not yet reported total funding or valuation, indicating it may be operating in stealth or early preclinical phases. As a private entity, Perceive's progress will depend on successful research milestones, financing, and potential partnerships to advance its programs toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead dry AMD candidate40% success
• H1 2027Preclinical proof-of-concept data in neuroprotection program50% success
• Q3 2026Series A financing or strategic partnership60% success